Breaking News

Almac, DSM Advance Biocatalysis Pact

February 19, 2013

Provides access to enzyme technologies and services for API manufacture

A collaboration between Almac and DSM Pharmaceutical Products in the field of biocatalysis to provide sustainable manufacturing services to the pharma industry, has successfully transferred enzymes for enzyme screening, process development and scale-up manufacture. The companies have completed multiple projects in the fields of ketoreductase, transaminase, bioöixdation and hydrolase.
The agreement grants both parties access to enzyme platform technologies and services for the manufacture of APIs and combines Almac’s rapid enzyme identification, scale-up and implementation into early phase projects, with DSM’s commercial manufacturing bioprocesses run on a multi-ton scale.
Dr. Tom Moody, head of Almac Biocatalysis, said, “The success of the projects undertaken between Almac and DSM already demonstrates there is a market for scalable green technologies to access difficult-to-make chiral chemicals.  Cost remains a prevalent issue within the industry and the introduction of enzymes into processes earlier in the drug discovery pipeline helps to drive cost down as projects move forward. Our collaboration is delivering real rewards to clients from both a technical and financial perspective.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important